Skip to main content
Medical information Clinical review pending

Genetic Testing

CCNO Gene Primary Ciliary Dyskinesia Type 29 Genetic Test

Genetic test using Next Generation Sequencing (NGS) to detect mutations in the CCNO gene associated with Primary Ciliary Dyskinesia (PCD), a condition causing chronic respiratory issues.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
A blood sample (typically 5-10ml in an EDTA tube) or extracted DNA.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is required for a blood draw. Confirm with the laboratory before booking if providing extracted DNA.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the CCNO Gene Primary Ciliary Dyskinesia Type 29 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Chronic respiratory symptoms (e.g., persistent cough, sinusitis, bronchiectasis).
  • ✓Recurrent respiratory infections.
  • ✓Unexplained infertility or male infertility.
  • ✓Situs inversus (organs reversed).
  • ✓Family history of Primary Ciliary Dyskinesia (PCD).
  • ✓Diagnosis confirmation after initial PCD screening tests.
02

In plain language

What this test helps you understand

This test helps identify individuals with mutations in the CCNO gene, confirming a diagnosis of PCD Type 29. Early diagnosis allows for appropriate management, including proactive respiratory care, treatment of infections, and potential fertility interventions. Genetic counseling can also help individuals and families understand the implications of the results.
This test identifies genetic mutations in the CCNO gene linked to Primary Ciliary Dyskinesia (PCD). PCD is a genetic disorder affecting cilia function, often leading to chronic respiratory problems, recurrent infections, and sometimes fertility issues. This test uses advanced Next Generation Sequencing (NGS) technology to analyze your DNA for specific variations in the CCNO gene. Understanding your genetic predisposition can help guide diagnosis and management strategies. This test is particularly relevant for individuals with persistent respiratory symptoms or a family history of PCD.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is required for a blood draw. Confirm with the laboratory before booking if providing extracted DNA.
SampleA blood sample (typically 5-10ml in an EDTA tube) or extracted DNA.
MethodologyNext Generation Sequencing (NGS) is used to analyze the DNA sequence of the CCNO gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the CCNO gene. PCD can be caused by mutations in other genes, which are not assessed by this test. A negative result does not completely rule out PCD. Results may be affected by sample quality. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

PCD is a rare, genetic disorder that affects the cilia, tiny hair-like structures lining the airways and other organs. Defective cilia lead to chronic respiratory problems, recurrent infections, and sometimes fertility issues.
Mutations in the CCNO gene are known to cause a specific type of PCD. This test targets these mutations to help confirm a diagnosis in individuals suspected of having this condition.
Your results will be interpreted by a healthcare professional, often in consultation with a genetic counselor. They will explain the findings and discuss potential implications for your health and family.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
Please provide any previous relevant test results to your doctor or the laboratory for review.
This test is available at our laboratory branches in Nairobi, Mombasa, and Kisumu. Home sample collection may also be available. Contact us for details.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp